Role of serum factors in epithelial cell responses to Helicobacter pylori infection in vitro

Human Gastric Epithelium Produces IL-4 and IL-4δ2 Isoform Only upon Helicobacter Pylori Infection

Recent evidence suggests that interleukin-4 (IL-4) is related to mucosal tolerance by which an injurious immune response is prevented, suppressed or shifted to a non-injurious response. We investigated the expression of IL-4 and its splice variant isoform IL-4δ2 in gastric epithelial cells of healthy subjects and gastritis patients infected with Helicobacter pylori (H. pylori) with or without the cag pathogenicity island ( cag-PAI). IL-4 and IL-4δ2 mRNAs were evaluated in microdissected gastric epithelium and in AGS cell lines co-cultured with H. pylori B128 or SSI strains. IL-4 mRNA was consistently detected in microdissected gastric epithelial cells from healthy subjects. The IL-4 mRNA expression was low in H. pylori-infected patients, and markedly reduced in cag-PAI-positive ones. IL-4δ2 mRNA was expressed on gastric epithelium of H. pylori-infected patients, but not in healthy subjects. The IL-452 expression was lower in cag-PAI-positive than in cag-PAI-negative H. pylori infected patients. AGS cells also produced IL-4 mRNA upon SSI strain stimulation, whereas IL-4δ2 mRNA expression was detected in AGS co-cultured with either SSI or B128 strains. An inverse correlation was documented between IL-4 and IL-482 mRNA expression by microdissected gastric epithelial cells and the score of gastritis. IL-4, but not IL-452, is expressed by gastric epithelium of healthy subjects, whereas IL-452 and lesser IL-4 mRNA are detectable in the gastric epithelium of H. pylori-infected patients. Data suggest that gastric epithelial cells might regulate the balance between tolerance and immune response by the fine tuning of IL-4 and IL-4δ2 expression.

Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori

Various approaches have been proposed to overcome the unpleasant side-effects associated with antibiotic treatment for Helicobacter pylori. The limited effectiveness of such approaches has forced researchers to consider alternative strategies to eliminate H. pylori infection. The plant alkaloid berberine is known to significantly reduce proliferation of H. pylori. To localize berberine to the site of H. pylori infection, this study developed a novel nanoparticle berberine carrier with a heparin shell. Analysis of a simulated gastrointestinal medium indicated that the proposed in vitro drug carrier system effectively controlled the release of berberine, which interacted specifically with the intercellular space at the site of H. pylori infection. Furthermore, the prepared nanoparticles significantly increased the suppressive effect of berberine on H. pylori growth while efficiently reducing cytotoxic effects in H. pylori-infected cells.

Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori

Various approaches have been proposed to overcome the unpleasant side-effects associated with antibiotic treatment for Helicobacter pylori. The limited effectiveness of such approaches has forced researchers to consider alternative strategies to eliminate H. pylori infection. The plant alkaloid berberine is known to significantly reduce proliferation of H. pylori. To localize berberine to the site of H. pylori infection, this study developed a novel nanoparticle berberine carrier with a heparin shell. Analysis of a simulated gastrointestinal medium indicated that the proposed in vitro drug carrier system effectively controlled the release of berberine, which interacted specifically with the intercellular space at the site of H. pylori infection. Furthermore, the prepared nanoparticles significantly increased the suppressive effect of berberine on H. pylori growth while efficiently reducing cytotoxic effects in H. pylori-infected cells.

Fifty years of Australian pediatric gastroenterology

When the Gastroenterological Society of Australia (GESA) began 50 years ago there were very few pediatric gastroenterologists in the world. The 'Mother' of Paediatric Gastroenterology was Australian Charlotte ('Charlo') Anderson who established one of the world's first pediatric gastroenterology units in Melbourne in the early 1960s. Her earlier work in Birmingham had identified gluten as the component of wheat responsible for celiac disease and helped separate maldigestion (cystic fibrosis) and mucosal malabsorption. The first comprehensive textbook of Paediatric Gastroenterology was edited by Charlotte Anderson and Valerie Burke in 1975. Rudge Townley succeeded Charlotte Anderson in Melbourne and went on to further develop small bowel biopsy techniques making it a safe, simple, and quick procedure that led to much greater understanding of small bowel disease and ultimately the discovery of Rotavirus by Ruth Bishop et al. and subsequently to Rotavirus immunization. Australian Paediatric Gastroenterology subsequently developed rapidly with units being established in all mainland capital cities by the end of the 1970s. The Australian Society of Paediatric Gastroenterology Hepatology and Nutrition (AuSPGHAN) was established in the 1980s. Australians have contributed significantly in many areas of gastroenterology in infants, children, and adolescents including celiac disease, cystic fibrosis, liver disease, transplantation, gastrointestinal infection, allergy, indigenous health, inflammatory bowel disease, gastrointestinal motility, and the development of novel tests of gastrointestinal function and basic science. There have also been major contributions to nutrition in cystic fibrosis, end-stage liver disease, and intestinal failure. The future of Australian Paediatric Gastroenterology is in good hands.